News | November 15, 2025
Aurobindo Pharma gets 9 observations from USFDA for Unit 2 of Eugia Pharma Specialities
The observations are procedural in nature and will be responded to within the stipulated time
The observations are procedural in nature and will be responded to within the stipulated time
The investment in land is Rs. 19.85 crore
Acquisition brings highly differentiated clinical-stage obesity candidates with potential to reshape the treatment landscape
Diroximel fumarate delayed-release capsules, 231 mg, are indicated for the treatment of relapsing forms of multiple sclerosis
This remarkable increase from 17 in 2021 ranks among the fastest for pharmaceutical companies, establishing Lupin as a leader in sustainable growth
Dexlansoprazole delayed-release capsules are a proton pump inhibitor
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The trial will evaluate safety endpoints including dose-limiting toxicities and adverse events
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Subscribe To Our Newsletter & Stay Updated
